Rapport Therapeutics (RAPP) Share-based Compensation (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Share-based Compensation data on file, last reported at $72.6 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 1697.03% year-over-year to $72.6 million in Q1 2026; TTM through Mar 2026 was $72.6 million, a 467.9% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, down 85.34% from the prior year.
• Share-based Compensation for Q1 2026 stood at $72.6 million, up from -$12.3 million in the prior quarter.
• Over the last five years, Share-based Compensation for RAPP reached as high as $72.6 million in Q1 2026 and fell as low as -$12.3 million in Q4 2025.
• Historically, Share-based Compensation has averaged $7.2 million across 4 years, with a median of $2.8 million in 2024.
• Across the five-year window, Share-based Compensation slumped 482.29% in 2025 and surged 1697.03% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $998000.0 in 2023, then surged by 221.44% to $3.2 million in 2024, then slumped by 482.29% to -$12.3 million in 2025, then surged by 691.98% to $72.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $72.6 million in Q1 2026, -$12.3 million in Q4 2025, and $4.7 million in Q3 2025.